PAHC icon

Phibro Animal Health

21.81 USD
-0.17
0.77%
At close Jan 31, 4:00 PM EST
After hours
21.81
+0.00
0.00%
1 day
-0.77%
5 days
-0.41%
1 month
3.86%
3 months
-5.67%
6 months
15.52%
Year to date
5.21%
1 year
101.76%
5 years
-8.05%
10 years
-21.77%
 

About: Phibro Animal Health Corp operates as a diversified animal health and mineral nutrition company. It develops, manufactures, and markets products for a range of food animals comprising poultry, swine, beef and dairy cattle, and aquaculture. The product portfolio of the company includes animal health products such as antibacterials, anticoccidials, nutritional specialty products and vaccines, and mineral nutrition products. The company operates through three segments, Animal Health, Mineral Nutrition, and Performance Products, of which key revenue is derived from the Animal Health segment which relates to the development, manufacturing, and marketing of antibacterials, nutritional specialty products, and vaccines. The entity sells its products in the U.S. and other international countries.

Employees: 1,940

0
Funds holding %
of 6,831 funds
Analysts bullish %

Fund manager confidence

Based on 2024 Q3 regulatory filings by fund managers ($100M+ AUM)

40% more first-time investments, than exits

New positions opened: 21 | Existing positions closed: 15

32% more capital invested

Capital invested by funds: $345M [Q2] → $457M (+$112M) [Q3]

14% more repeat investments, than reductions

Existing positions increased: 56 | Existing positions reduced: 49

4% more funds holding

Funds holding: 141 [Q2] → 146 (+5) [Q3]

1.44% less ownership

Funds ownership: 101.24% [Q2] → 99.8% (-1.44%) [Q3]

Research analyst outlook

2 Wall Street Analysts provided 1 year price targets over the past 3 months

Low target
$20
8%
downside
Avg. target
$23
3%
upside
High target
$25
15%
upside

2 analyst ratings

positive
0%
neutral
50%
negative
50%
Morgan Stanley
Erin Wright
67% 1-year accuracy
18 / 27 met price target
15%upside
$25
Equal-Weight
Maintained
17 Dec 2024
Barclays
Balaji Prasad
44% 1-year accuracy
18 / 41 met price target
8%downside
$20
Underweight
Maintained
12 Nov 2024

Financial journalist opinion

Based on 14 articles about PAHC published over the past 30 days

Neutral
Zacks Investment Research
2 days ago
Phibro Animal Health (PAHC) Earnings Expected to Grow: Should You Buy?
Phibro (PAHC) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Phibro Animal Health (PAHC) Earnings Expected to Grow: Should You Buy?
Positive
Zacks Investment Research
2 days ago
Here's Why Phibro Animal Health (PAHC) is a Strong Value Stock
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Here's Why Phibro Animal Health (PAHC) is a Strong Value Stock
Positive
Zacks Investment Research
1 week ago
Phibro (PAHC) is an Incredible Growth Stock: 3 Reasons Why
Phibro (PAHC) possesses solid growth attributes, which could help it handily outperform the market.
Phibro (PAHC) is an Incredible Growth Stock: 3 Reasons Why
Positive
Zacks Investment Research
1 week ago
PAHC vs. SYK: Which Stock Should Value Investors Buy Now?
Investors interested in stocks from the Medical - Products sector have probably already heard of Phibro Animal Health (PAHC) and Stryker (SYK). But which of these two stocks presents investors with the better value opportunity right now?
PAHC vs. SYK: Which Stock Should Value Investors Buy Now?
Positive
Zacks Investment Research
1 week ago
Is Phibro Animal Health (PAHC) Stock Undervalued Right Now?
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
Is Phibro Animal Health (PAHC) Stock Undervalued Right Now?
Neutral
Business Wire
1 week ago
Phibro Animal Health Corporation Announces the Appointment of Joyce J. Lee to Its Board of Directors
TEANECK, N.J.--(BUSINESS WIRE)--The Board of Directors of Phibro Animal Health Corporation (Nasdaq: PAHC) today announced the appointment of Joyce J. Lee, MBA, as a Class II director of the Company, effective immediately. Ms. Lee will be an independent director. Her appointment fills a current vacancy and increases Board membership to nine directors, 6 of whom are independent directors. Ms. Lee brings a wealth of expertise and leadership to our Board of Directors, most recently serving as Presi.
Phibro Animal Health Corporation Announces the Appointment of Joyce J. Lee to Its Board of Directors
Neutral
Business Wire
1 week ago
Phibro Animal Health Corporation to Host Webcast and Conference Call on Second Quarter Results
TEANECK, N.J.--(BUSINESS WIRE)--Phibro Animal Health Corporation (Nasdaq: PAHC) expects to announce its second quarter financial results on Wednesday, February 5, 2025, after the market closes. Phibro management will host a conference call and webcast on Thursday, February 6, 2025, at 9:00 AM Eastern Time. Interested parties are invited to listen to the conference call and view the presentation slides by visiting https://investors.pahc.com. The discussion will also be available by dialing +1 (8.
Phibro Animal Health Corporation to Host Webcast and Conference Call on Second Quarter Results
Positive
Zacks Investment Research
2 weeks ago
Why Phibro Animal Health (PAHC) is a Top Value Stock for the Long-Term
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Why Phibro Animal Health (PAHC) is a Top Value Stock for the Long-Term
Positive
Zacks Investment Research
3 weeks ago
Expanding Global Network, Vaccine Sales Support PAHC Stock
Phibro Animal Health is focusing on new developments along with incremental registrations and growing volumes of existing vaccine technologies.
Expanding Global Network, Vaccine Sales Support PAHC Stock
Positive
Zacks Investment Research
3 weeks ago
3 Reasons Growth Investors Will Love Phibro (PAHC)
Phibro (PAHC) possesses solid growth attributes, which could help it handily outperform the market.
3 Reasons Growth Investors Will Love Phibro (PAHC)
Charts implemented using Lightweight Charts™